A clinical phase II study of a non-anthracycline sequential combination of cisplatin-vinorelbine followed by docetaxel as first-line treatment in metastatic breast cancer

Oncology

Volumn 70, Issue 5, 2007, Pages 330-338

  Shamseddine, Ali I ^a   Otrock, Zaher K ^a   Khalifeh, Mohamad J ^a   Yassine, Hanan R ^a   Charafeddine, Maya ^a   Abdel Khalek, Zeina ^a   Chehal, Aref ^a   Bitar, Nizar ^b   Jalloul, Rahif ^c   Dheiny, Moussa ^d   Dandashi, Azzam ^e   Wehbeh, Mahmoud ^d   El Saghir, Nagi S ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b Sahel General Hospital   (Lebanon)

^c MAKASSED GENERAL HOSPITAL   (Lebanon)

^d Hammoud Hospital   (Lebanon)

^e Islamic Hospital Tripoli   (Lebanon)

Author keywords

Cisplatin; Docetaxel; Metastatic breast cancer; Non anthracycline combination; Phase II study; Vinorelbine

Indexed keywords

ANTHRACYCLINE; CISPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; DOCETAXEL; METOCLOPRAMIDE; NAVELBINE; SEROTONIN ANTAGONIST;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG DOSE REGIMEN; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CISPLATIN; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FEVER; FOLLOW-UP STUDIES; HUMANS; KIDNEY; MIDDLE AGED; NEOPLASM STAGING; NEUTROPENIA; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME; VINBLASTINE; VOMITING;

EID: 33846148365     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000097945     Document Type: Article

References (36)

1. Esteva FJ, Valero V, Pusztai L, Boehnke-Michaud L, Buzdar AU, Hortobagyi GN: Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond. Oncologist 2001;6:133-146.
2. Biganzoli L, Minisini A, Aapro M, Di Leo A: Chemotherapy for metastatic breast cancer. Curr Opin Obstet Gynecol 2004;16:37-41.
3. Ershler WB: Capecitabine monotherapy: safe and effective treatment for metastatic breast cancer. Oncologist 2006;11:325-335.
4. Costanza ME, Weiss RB, Henderson IC, Norton L, Berry DA, Cirrincione C, Winer E, Wood WC, Frei E 3rd, McIntyre OR, Schilsky RL: Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: report of a randomized study - Cancer and Leukemia Group B 8642. J Clin Oncol 1999;17:1397-1406.
5. Henderson IC: Chemotherapy of breast cancer. A general overview. Cancer 1983;51(suppl 12):2553-2559.
6. Jones SE, Durie BG, Salmon SE: Combination chemotherapy with adriamycin and cyclophosphamide for advanced breast cancer. Cancer 1975;36:90-97.
7. Danova M, Porta C, Ferrari S, Riccardi A: Strategies of medical treatment for metastatic breast cancer (review). Int J Oncol 2001;19:733-739.
8. Esteva FJ: Monoclonal antibodies, small molecules, and vaccines in the treatment of breast cancer. Oncologist 2004;9(suppl 3):4-9.
9. Fumoleau P, Delgado FM, Delozier T, Monnier A, Gil Delgado MA, Kerbrat P, Garcia-Giralt E, Keiling R, Namer M, Closon MT, et al: Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 1993;11:1245-1252.
10. Garcia-Conde J, Lluch A, Martin M, Casado A, Gervasio H, De Oliveira C, De Pablo JL, Gorostiaga J, Giron GC, Cervantes A, et al: Phase II trial of weekly IV vinorelbine in first-line advanced breast cancer chemotherapy. Ann Oncol 1994;5:854-857.
11. Weber BL, Vogel C, Jones S, Harvey H, Hutchins L, Bigley J, Hohneker J: Intravenous vinorelbine as first-line and secondline therapy in advanced breast cancer. J Clin Oncol 1995;13:2722-2730.
12. Bruno S, Puerto VL, Mickiewicz E, Hegg R, Texeira LC, Gaitan L, Martinez L, Fernandez O, Otero J, Kesselring G, et al: Phase II trial of weekly iv vinorelbine as a single agent in first-line advanced breast cancer chemotherapy. The Latin-American experience. Am J Clin Oncol 1995;18:392-396.
13. Fumoleau P, Fety R, Delecroix V, Perrocheau G, Azli N: Docetaxel combined with vinorelbine: phase I results and new study designs. Oncology (Williston Park) 1997;11(suppl 6):29-31.
14. Romero Acuna L, Langhi M, Perez J, Romero Acuna J, Machiavelli M, Lacava J, Vallejo C, Romero A, Fasce H, Ortiz E, Grasso S, Amato S, Rodriguez R, Barbieri M, Leone B: Vinorelbine and paclitaxel as first-line chemotherapy in metastatic breast cancer. J Clin Oncol 1999;17:74-81.
15. Martin M, Garcia-Donas J, Casado A, de la Gandara I, Perez-Segura P, Garcia-Saenz JA, Ibanez G, Loboff B, Garcia-Ledo G, Moreno F, Grande E, Diaz-Rubio E: Phase II study of pegylated liposomal doxorubicin plus vinorelbine in breast cancer with previous anthracycline exposure. Clin Breast Cancer 2004;5:353-357.
16. Burstein HJ, Kuter I, Campos SM, Gelman RS, Tribou L, Parker LM, Manola J, Younger J, Matulonis U, Bunnell CA, Partridge AH, Richardson PG, Clarke K, Shulman LN, Winer EP: Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 2001;19:2722-2730.
17. Sledge GW Jr, Loehrer PJ Sr, Roth BJ, Einhorn LH: Cisplatin as first-line therapy for metastatic breast cancer. J Clin Oncol 1988;6:1811-1814.
18. Kolaric K, Roth A: Phase II trial of cis-dichlorodiammine platinum (cis-DDP) for antitumorigenic activity in previously untreated patients with metastatic breast cancer. Cancer Chemother Pharmacol 1983;11:108-112.
19. Henderson IC, Garber JE, Breitneyer JB: Comprehensive management of disseminated breast cancer. Cancer 1990;66:1439-1448.
20. Bernard A, Antoine EC, Gozy M, et al: Docetaxel and cisplatin in anthracycline-pretreated advanced breast cancer: results of a phase II pilot study (abstract 491). Proc Am Soc Clin Oncol 1998;17:128a.
21. Marty M, Extra JM, Cottu PH, Espie M: Prospects with docetaxel in the treatment of patients with breast cancer. Eur J Cancer 1997;33(suppl 7):S26-S29.
22. Fulton B, Spencer CM: Docetaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer. Drugs 1996;51:1075-1092.
23. Nabholtz JM: Docetaxel-anthracycline combinations in metastatic breast cancer. Breast Cancer Res Treat 2003;79(suppl 1):S3-S9.
24. Ahn JH, Kim SB, Sohn HJ, Lee JS, Kang YK, Kun Kim W: Docetaxel and cisplatin combination chemotherapy in metastatic breast cancer patients with previous exposure to anthracyclines. Breast 2005;14:304-309.
25. Shamseddine AI, Taher A, Dabaja B, Dandashi A, Salem Z, El Saghir NS: Combination cisplatin-vinorelbine for relapsed and chemotherapy-pretreated metastatic breast cancer. Am J Clin Oncol 1999;22:298-302.
26. Shamseddine A, Khalifeh M, Chehal A, Saliba T, Saliba T, Mourad YA, Taher A, Jalloul R, Bitar N, Dandashi A, Abbas J, Geara FB: A clinical phase II study of cisplatinum and vinorelbine (PVn) in advanced breast carcinoma (ABC). Am J Clin Oncol 2005;28:393-398.
27. Paridaens R, Van Aelst F, Georgoulias V, Samonnig H, Cocquyt V, Zielinski C, Hausmaninger H, Willemse P, Boudraa Y, Wildiers J, Ramazeilles C, Azli N: A randomized phase II study of alternating and sequential regimens of docetaxel and doxorubicin as first-line chemotherapy for metastatic breast cancer. Ann Oncol 2003;14:433-440.
28. Khayat D, Chollet P, Antoine EC, Monfardini S, Ambrosini G, Benhammouda A, Mazen MF, Sorio R, Borg-Olivier O, Riva A, Ramazeilles C, Azli N: Phase II study of sequential administration of docetaxel followed by doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer. J Clin Oncol 2001;19:3367-3375.
29. Perez EA, Geeraerts L, Suman VJ, Adjei AA, Baron AT, Hatfield AK, Maihle N, Michalak JC, Kuross SA, Kugler JW, Lafky JM, Ingle JN: A randomized phase II study of sequential docetaxel and doxorubicin/cyclophosphamide in patients with metastatic breast cancer. Ann Oncol 2002;13:1225-1235.
30. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
31. Perez EA, Suman VJ, Fitch TR, Mailliard JA, Ingle JN, Cole JT, Veeder MH, Flynn PJ, Walsh DJ, Addo FK: A phase II trial of docetaxel and carboplatin as first-line chemotherapy for metastatic breast cancer: NCCTG study N9932. Oncology 2005;69:117-121.
32. Mayordomo JI, Milla A, Morales S, Yubero A, Lorenzo A, Baena JM, Modolell A, Sanz J, Illarramendi J, Garcia MJ, Machengs I, Burrilo MA, Tres A: Biweekly docetaxel and vinorelbine as first-line chemotherapy in metastatic breast cancer. Clin Breast Cancer 2004;5:131-135.
33. Mohran TZ: Gemcitabine and cisplatin combination chemotherapy as a first-line treatment in patients with metastatic breast cancer. J Egypt Natl Cancer Inst 2004;16:8-14.
34. Anton A, Hornedo J, Lluch A, Massuti B, Corral M, Colomer R: A phase II study of sequential docetaxel followed by doxorubicin/cyclophosphamide as first-line chemotherapy for metastatic breast cancer. Clin Breast Cancer 2003;4:286-291.
35. Demiray M, Kurt E, Evrensel T, Kanat O, Arslan M, Saraydaroglu O, Ercan I, Gonullu G, Gokgoz S, Topal U, Tolunay S, Tasdelen I, Manavoglu O: Phase II study of gemcitabine plus paclitaxel in metastatic breast cancer patients with prior anthracycline exposure. Cancer Invest 2005;23:386-391.
36. Morabito A, Filippelli G, Palmeri S, Cascinu S, Ferrau F, Zagonel V, Gattuso D, Catalano V, Capaccetti B, Franciosi V, Accurso V, Scinto F, Gasparini G: The combination of gemcitabine and vinorelbine is an active regimen as second-line therapy in patients with metastatic breast cancer pretreated with taxanes and/or anthracyclines: a phase I-II study. Breast Cancer Res Treat 2003;78:29-36.